Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide with Rituximab and Methotrexate for Newly-diagnosed PCNSL
NCT06554561Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate. Started Aug 2024; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06554561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554561.